GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - GRAIL, Inc. reported significant commercial growth in 2025, with total revenue increasing by 17% year-over-year to $147.2 million and U.S. Galleri revenue growing by 26% to $136.8 million [1][4] - The company completed its Premarket Approval (PMA) submission to the FDA for the Galleri test and shared positive topline results from the NHS-Galleri trial, indicating a substantial reduction in Stage IV cancer diagnoses [1][2] - GRAIL's financial position remains strong, with cash and cash equivalents totaling $904.4 million as of December 31, 2025, providing financial flexibility for future growth [1][4] Financial Performance - For Q4 2025, total revenue was $43.6 million, a 14% increase year-over-year, while U.S. Galleri revenue reached $41.3 million, up 31% [1][4] - The net loss for Q4 2025 was $99.2 million, which includes $34.6 million in amortization related to the Illumina acquisition [1][4] - For the full year 2025, the net loss was $408.4 million, an improvement of $1.6 billion or 80% compared to the previous year [1][4] Business Highlights - GRAIL expanded access to the Galleri test through partnerships with digital health platforms, including the launch of the Hims & Hers Multi-Cancer Test [1][2] - The company completed the analysis of the full 35,000 participant PATHFINDER 2 study, demonstrating consistent performance with earlier results [1][2] - The NHS-Galleri trial results showed that adding Galleri to standard care screening significantly increased the detection rates of early-stage cancers [1][2] Cash Position - As of December 31, 2025, GRAIL had cash, cash equivalents, and short-term marketable securities totaling $904.4 million, ensuring operational sustainability into 2030 [1][4] Future Outlook - GRAIL anticipates continued commercial growth in 2026, with plans for new partnerships in digital health and further integration into health systems [1][2] - Detailed results from the PATHFINDER 2 and NHS-Galleri trials are expected to be presented in mid-2026 [1][2]